Prognostic importance of MRI detected extramural venous invasion in rectal cancer: a literature review and systematic meta-analysis
Extramural venous invasion (EMVI) is recognised to be a poor prognostic factor in rectal cancer. There are well documented limitations associated with pathology detection of EMVI, including variable reporting and the inability for it to be used preoperatively to guide neoadjuvant treatment. MRI detected EMVI (mrEMVI) has been proposed as an imaging biomarker. This review assesses the prognostic significance of mrEMVI on survival outcomes and whether regression of mrEMVI after neoadjuvant therapy is associated with improvements in survival. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 10, 2021 Category: Radiology Authors: J.J. Tan, R.V. Carten, A. Babiker, M. Abulafi, A.C. Lord, G. Brown Tags: Clinical Investigation Source Type: research

First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies
Total marrow irradiation  (TMI) has significantly advanced radiation conditioning for hematopoietic cell transplantation in hematological malignancies by reducing conditioning-induced toxicities and improving survival outcomes in relapsed/refractory patients. However, the relapse rate remains high, and the lack of a prec linical TMI model has hindered scientific advancements. To accelerate TMI translation to the clinic, we developed a TMI delivery system in pre-clinical models. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 10, 2021 Category: Radiology Authors: Darren Zuro, Srideshikan Sargur Madabushi, Jamison Brooks, Bihong T. Chen, Janagama Goud, Amandeep Salhotra, Joo Y. Song, Liliana Echavarria Parra, Antonio Pierini, James F Sanchez, Anthony Stein, Monzr Al Malki, Marcin Kortylewski, Jeffrey Y.C. Wong, Par Source Type: research

Radiation-Induced Autophagy in Human Pancreatic Cancer Cells is Critically Dependent on G2 Checkpoint Activation: A Mechanism of Radioresistance in Pancreatic Cancer
Autophagy and cell-cycle checkpoints act in concert to confer cellular radioresistance. We investigated the functional interaction between radiation-induced autophagy and G2 checkpoint activation in highly radioresistant human pancreatic ductal adenocarcinoma (PDAC) cells. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 7, 2021 Category: Radiology Authors: Motofumi Suzuki, Mayuka Anko, Maki Ohara, Ken-ichiro Matsumoto, Sumitaka Hasegawa Tags: Biology Contribution Source Type: research

Quality of life is independently associated with neurocognitive function in brain tumor patients: analysis of a prospective clinical trial
We conducted the first prospective longitudinal study examining the independent association between patient-reported hrQoL (physical, social/family, emotional, functional, and brain cancer-specific) and neurocognitive function (NCF), while controlling for mood symptoms in primary brain tumor patients. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 5, 2021 Category: Radiology Authors: Mia Salans, Michelle D. Tibbs, Minh-Phuong Huynh-Le, Anthony Yip, Kathryn Tringale, Roshan Karunamuni, Ronghui Xu, Anny Reyes, Anna Christina Macari, Tonya Pan-Weisz, Carrie R. McDonald, Jona A. Hattangadi-Gluth Tags: Clinical Investigation Source Type: research

Forecasting Individual Patient Response to Radiotherapy in Head and Neck Cancer with a Dynamic Carrying Capacity Model
Purpose: In order for radiotherapy to enter the realm of personalized medicine it will be necessary to model and predict individual patient responses to radiotherapy.Methods and Materials: Here we model tumor dynamics as logistic growth and the effect of radiation as a reduction in the tumor carrying capacity, motivated by the impact of radiation on the tumor microenvironment. The model was assessed on weekly tumor volume data collected for two independent cohorts of head and neck cancer patients from XXXX1 and XXXX2 that received 66-70 Gy in standard daily fractions or with accelerated fractionation. (Source: Internationa...
Source: International Journal of Radiation Oncology * Biology * Physics - June 5, 2021 Category: Radiology Authors: Mohammad U. Zahid, Nuverah Mohsin, Abdallah S.R. Mohamed, Jimmy J. Caudell, Louis B. Harrison, Clifton D. Fuller, Eduardo G. Moros, Heiko Enderling Tags: Physics Contribution Source Type: research

Phase 3 randomized trial of topical steroid versus placebo for prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiation
Purpose: Radiation dermatitis is one of the most common acute toxicities induced by chemoradiotherapy (CRT) for head and neck cancer (HNC). The benefit of topical steroids in the management of radiation dermatitis is still unclear. This phase 3, multi-institutional, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of topical steroids for radiation dermatitis in  patients with locally advanced HNC receiving CRT.Methods and Materials: Eligible patients were scheduled to receive bilateral neck irradiation (≥ 66 Gy) with concurrent cisplatin (≥ 200 mg/m2) as definitive or postoper...
Source: International Journal of Radiation Oncology * Biology * Physics - June 5, 2021 Category: Radiology Authors: Tomoya Yokota, Sadamoto Zenda, Ichiro Ota, Tomoko Yamazaki, Takuhiro Yamaguchi, Takenori Ogawa, Hiroyuki Tachibana, Takashi Toshiyasu, Akihiro Homma, Tempei Miyaji, Tomoe Mashiko, Satoshi Hamauchi, Kuniko Tominaga, Shinobu Ishii, Yui Otani, Noriko Orito, Source Type: research

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study
The excellent prognosis of patients with low-risk human papillomavirus (HPV)- associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiation therapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an epidermal growth factor receptor targeting antibody, when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 4, 2021 Category: Radiology Authors: Danny Rischin, Madeleine King, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E. Jackson, Mathias Bressel, Alan Herschtal, Richard Fisher, Tsien Fua, Charles Lin, Chen Liu, Brett G.M. Hughes, Margaret McGrath, Lachlan McDowell, Tags: Clinical Investigation Source Type: research

A Trans-Atlantic Voyage of Extended ADT With Local Radiation
This is a patient with likely>10-year life expectancy with high-volume1 (11 of 12 cores) high-risk (Gleason 8, prostate-specific antigen 30) prostate cancer, and therefore aggressive treatment with curative intent is warranted. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Ronald C. Chen Source Type: research

Follow the Trials
(Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Ashesh B. Jani Source Type: research

Understanding Competing Risks
You are debating with a urologist about the relative merits and harms of primary radiation therapy (RT) versus prostatectomy for high-risk prostate cancer. The urologist warns all of her patients about the risks of late effects from both RT and androgen deprivation therapy (ADT) and the secondary cancer risk after RT. In the absence of randomized trials, to inform this debate using an evidence-based approach, you have collected detailed, longitudinal data on the outcomes of several hundred patients with up to 10 years of follow-up. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Ramsankar Basak, Hitesh Mistry, Ronald C. Chen Tags: Statistics for the People Source Type: research

Not So “Active” Surveillance
In 1987, prostate-specific antigen (PSA) was introduced for prostate cancer screening. Widespread adoption of PSA screening resulted in a significantly increased number of incident cases and a significantly reduced number of cases of metastatic disease at presentation.1 However, survival benefits have come at the cost of significant overdiagnosis and corresponding overtreatment, resulting in significant subsequent controversy over the role of PSA screening for prostate cancer.2 Notably, patients with low-risk prostate cancer are the least likely to experience disease progression and are most at risk of morbidity due to ove...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Christopher J.D. Wallis, Laurence Klotz, Raj Satkunasivam, Zachary Klaassen Tags: Editorial Source Type: research

In Regard to Parry et  al
The study by Parry et  al1 addressed the impact of whole pelvic radiation therapy (WPRT) on patient-reported outcomes (PROMs) in high-risk prostate cancer using information from a national prostate cancer database. No clinically meaningful difference in the PROMs was reported between WPRT and prostate-only radiation the rapy (PORT). They also suggest that “results from studies using clinician reported outcome measures are in line with studies using PROMs.” We would like to highlight 2 recent randomized trials that have used PROMs and physician-reported toxicity to compare PORT and WPRT, which were surprisi...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Vedang Murthy, Shashank Srinivasan Tags: Comments Source Type: research

In Reply to Khalifa and Sargos
We thank the authors for their comments1 on our publication titled “Phase I trial of atezolizumab plus trimodal therapy (TMT) in patients with localized muscle-invasive bladder cancer (MIBC)” published in this journal.2 (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Gautier Marcq, Luis Souhami, Wassim Kassouf Tags: Comments Source Type: research

In Regard to Marcq et  al
We read with interest the article titled “Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer.”1 The authors should be congratulated because this is the first published report of the evaluation of concomitant use of immune check point inhibitor (ICI) with concurrent chemoradioth erapy for localized muscle-invasive bladder cancer (MIBC). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: J. Khalifa, P. Sargos Tags: Comments Source Type: research

In Regard to Salama et  al
We congratulate Drs. Salama, Floyd, Willett, and Kirsch on the development of the Radiation Oncology Residents program to support physician scientist career development at Duke University.1 We agree that physician scientist career development is critical to the future of our field. The current structure of residency training in radiation oncology provides inadequate time and support for most trainees to develop research projects that can successfully compete for funding at the junior faculty level. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Stephanie Perkins, Dennis E. Hallahan, Julie K. Schwarz Tags: Comments Source Type: research

Challenges and Opportunities for Radiation Oncology Residency Programs During the 2020-2021 Virtual Residency Match
In our previous study,1 we reported the underutilization of social media (SM) resources among radiation oncology (RO) residency programs in anticipation of the COVID-driven 2020 to 2021 virtual residency match. However, it remains unknown whether SM utilization among RO residency programs has since improved. Additionally, it is unclear whether individual SM platforms offer the same value in guiding applicants in program selection. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Bismarck C. Odei, Junu Bae, Dalia Littman, Alejandra Zaleta Lastra, Austin Morgan, Temitope Agabalogun, Sofia Herrera, James Odei, Denise Fabian, Fumiko Chino Tags: Comments Source Type: research

Erratum to: Abdel-Wahab M, Rosenblatt E, Prajogi B, Zubizarretta E, Mikhail M. Opportunities in Telemedicine, Lessons Learned After COVID-19 and the Way Into the Future. Int J Radiat Oncol Biol Phys 2020:108(2);438-443.
In the article: Opportunities in Telemedicine, Lessons Learned After COVID-19 and the Way Into the Future (Telemedicine, Radiation Oncology, International Atomic Energy Agency, Vienna, Austria, Received Jul 6, 2020. Accepted for publication Jul 6, 2020), the author ’s name Eduardo Zubizarreta was misspelled. In the original submission he was listed as Eduardo Zubizarretta (two “t”s) while the correct spelling is Zubizarreta (one “t”). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Tags: Erratum Source Type: research

Dose Escalation for Oligometastatic Disease: Is More Better?
Most of the randomized evidence for the optimal radiotherapeutic treatment of metastases was conducted in polymetastatic disease with the goal of symptom management. In particular, for painful bone metastasis, numerous trials have compared various lower dose radiation therapy schedules (eg, 8 Gy × 1, 4 Gy × 5, 3 Gy × 10), with no differences in pain response.1-3 Although the primary goal was met, many showed pain control durability of only 12 weeks and high rates of local failure in the few trials that tracked this outcome. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Tithi Biswas, Daniel E. Spratt Tags: Editorial Source Type: research

In Regard to Parry et  al
We congratulate Parry et  al for their achievement in reporting outcome metrics on radical radiation therapy for intermediate, high-risk, and locally advanced prostate cancer from the UK National Prostate Cancer Audit.1 We also welcome their suggestion of a randomized clinical trial to prospectively compare the efficacy o f the different brachytherapy boost techniques as well as their associated morbidities. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Stephen Langley, Robert Laing, Sara Khaksar, Carla Perna, Sophie Otter, Sheel Mehta, Santiago Uribe-Lewis, Jennifer Uribe Tags: Comments Source Type: research

In Reply to Langley et  al
We welcome the comments from Langley et  al1 with respect to our recent publication on the impact of brachytherapy boost on outcomes in patients receiving external beam radiation therapy (EBRT) for prostate cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Matthew G. Parry, Julie Nossiter, Arunan Sujenthiran, Thomas E. Cowling, Rajan N. Patel, Melanie Morris, Brendan Berry, Paul Cathcart, Noel W. Clarke, Jan van der Meulen, Ajay Aggarwal Tags: Comments Source Type: research

In Regard to Zelefsky et  al
In a phase 3 multicenter randomized trial, Zelefsky et  al compared 24 Gy single-dose radiation therapy (SDRT) to 27 Gy (3-fraction) stereotactic body radiation therapy in 117 patients experiencing oligometastatic progression in 154 lesions.1 The most prominent cancers in this trial were prostate cancer (47%), lung cancer (9.4%), and colorectal cancer (8.5%). The majority of the lesions (88%) were bone lesions. SDRT was associated with superior local control (LC) and improvement in metastatic progression without additional toxicity. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Kato Rans, Gert De Meerleer, Steven Joniau, Adinda Baten, Patrick Berkovic, Maarten Lambrecht, Charlien Berghen Tags: Comments Source Type: research

In Reply to Sabour
We thank the author of this letter to the editor1 for their interest in our paper and welcome the opportunity to further discuss our results. With cone beam computed tomography scans analyzed for a total of 69 patients, we acknowledge the data set is on the smaller end for modeling purposes. Therefore, a small number of candidate predictors (4 in total: 1 mean esophageal dose and 3 esophageal expansion magnitudes) were investigated, the significance level was Bonferroni corrected to P (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Sadegh R. Alam, Pengpeng Zhang, Si-Yuan Zhang, Andreas Rimner, Neelam Tyagi, Yu-Chi Hu, Wei Lu, Ellen D. Yorke, Joseph O. Deasy, Maria Thor Tags: Comments Source Type: research

In Reply to Rans et  al
We appreciate the comments made by Rans et  al1 and concur that the difference in cumulative incidence of local relapse in our phase 3 randomized study2 reflects the increased biologically effective dose (BED) of 24 Gy single-dose radiation therapy (SDRT) compared with 3 × 9 Gy stereotactic body radiation therapy. When this protocol was de signed, there was already evidence from our early phase 1-2 SDRT studies3,4 that 24 Gy SDRT achieved high rates of prolonged local relapse-free survival, apparently superior to lower BED SDRT or low- to intermediate-BED multifraction stereotactic body radiation therapy regimen...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Michael J. Zelefsky, Carlo Greco, Yoshiya Yamada, Simon N. Powell, Zvi Fuks Tags: Comments Source Type: research

In Regard to Alam et  al
I read with interest the paper by Alam et  al published in the International Journal of Radiation Oncology, Biology, Physics.1 Acute esophagitis (AE) is a common dose-limiting toxicity in radiation therapy (RT) of locally advanced non-small cell lung cancer. The authors aimed to develop an early AE prediction model from weekly accumulated esophagus dose and its associated local volumetric change. Fifty-one patients with locally advanced non-small cell lung cancer were treated via intensity modulated RT to 60 Gy in 2 Gy fractions with concurrent chemotherapy and had weekly cone beam computed tomography (CBCT) scans. (S...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Siamak Sabour Tags: Comments Source Type: research

Advances in Image-Guided Adaptive Radiation Therapy
Image-guided radiation therapy (IGRT) is recognized as one of the major advances in the field of radiation therapy. Image-based couch shifts to correct for patient position based on internal anatomy can be seen as the earliest form of adaptive radiation therapy (ART). Recently, this concept has been reaching new heights, with progress in (1) time scale (ie, moving toward real-time adaptive techniques), (2) tissue visualization through improved image quality and soft tissue contrast, and (3) biological adaption through incorporation of measures of biological response and organ function. (Source: International Journal of Rad...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Jenny Bertholet, Yevgeniy Vinogradskiy, Yanle Hu, David J. Carlson Source Type: research

Prostate Brachytherapy Boost: Where Are We and Where Are We Going
For unfavorable intermediate- and high-risk prostate cancer, there are at least 10 radiation therapy dose and fractionation schedules with acceptable efficacy and toxicity, according to the most recent National Comprehensive Cancer Network (NCCN) clinical practice guidelines (v1.2021). This includes 4 different low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy boost options in combination with either conventionally fractionated or hypofractionated external beam radiation therapy (EBRT). How do we interpret this dizzying array of complexity? Costs aside, differing fractionation schemes are of less concern if they ar...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Robert T. Dess Tags: Editorial Source Type: research

Can Hypofractionation and Immune Modulation Coexist?
The past few years have seen a renewed interest in bladder-preserving treatment for patients with muscle-invasive bladder cancer (MIBC). Although there is no doubt that bladder preservation is an excellent local treatment with high levels of control and low levels of late toxicity,1 about half of patients will die of metastatic disease within 5 years. At the heart of this strategy is radical trimodality treatment (TMT), comprising tumor resection followed by radiation therapy with a radiosensitizer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Richard C. Walshaw, Peter J. Hoskin, Ananya Choudhury Tags: Editorial Source Type: research

Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
A 70-year-old male patient with neither significant comorbidities nor symptoms was referred to our department for prostate cancer radiation therapy. The last prostate-specific antigen value was 30 ng/mL. Transrectal ultrasound guided biopsy findings confirmed the presence of prostatic adenocarcinoma without neuroendocrine component in 11 out of 12 cores, with the following distribution: in 3 of 3 cores in the right lobe, Gleason score (GS) was 7(4 + 3); in the left lobe, 5 cores corresponded to GS 7 (4 + 3), 2 cores were GS 8(4 + 4), and 1 was GS 7(3 + 4). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Yazid Belkacemi, Gabriele Coraggio, Gokoulakrichenane Loganadane, Transatlantic Radiation Oncology Network (TRONE) Source Type: research

Quality of Life After Prostate Cancer Treatment
Multiple management options are available for clinically localized prostate cancer, including definitive external beam radiation therapy (EBRT), radical prostatectomy (RP), brachytherapy (BT), and, for patients with low-risk and favorable intermediate-risk disease, active surveillance.1 Given the high cure rate and long life expectancy after treatment, quality of life (QOL) often remains the paramount factor in decision-making for patients with clinically localized disease.2 Several validated patient-reported outcome (PRO) instruments exist for prostate cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Amar U. Kishan, Sean P. Collins Tags: Editorial Source Type: research

Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
The proPSMA study has recently shown the superiority of PSMA positron emission tomography (PET) to conventional imaging in detecting lymph nodes and distant disease in patients with high-risk prostate cancer.1 Accordingly, we have been using PSMA PET imaging for initial staging of patients with high-risk prostate cancer whenever possible. Notably, in our experience, PSMA PET is not widely covered by insurance companies in the initial staging. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Osama Mohamad, Felix Feng Source Type: research

Risk-Adapted Radiation Deintensification in Children and Young Adults With Soft Tissue Sarcoma: New Questions Arise and Prior Questions Resurface
From numerous angles, the article by Million et  al1 represents a landmark effort. First, beyond rhabdomyosarcoma, prospective cooperative group studies on soft tissue sarcomas are rare. To our knowledge, none of the adult National Cancer Institute cooperative groups maintain a standing sarcoma committee. Accordingly, progress has been slow, and practice is often derived from large single-institution series. The results of ARST0332 are valuable from that standpoint alone. Additionally, although this study was led by the Children's Oncology Group, it includes patients aged 18 to 30 years. (Source: International Journal...
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Authors: Daniel J. Indelicato, Meena Bedi Tags: Editorial Source Type: research

Issue Highlights
Bertholet et al (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Source Type: research

Meetings
June 9-12, 2021 EACR 2021 Virtual Congress online (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 3, 2021 Category: Radiology Source Type: research

Salivary and Dental Complications in Childhood Cancer Survivors Treated With Radiation Therapy to the Head and Neck: A Pediatric Normal Tissue Effects in the Clinic (PENTEC) Comprehensive Review
Radiation therapy (RT) to the head and neck (H&N) region is critical in the management of various pediatric malignancies; however, it may result in late toxicity. This comprehensive review from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative focused on salivary dysfunction and dental abnormalities in survivors who received RT to the H&N region as children. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 29, 2021 Category: Radiology Authors: Sarah A. Milgrom, Peter van Luijk, Ramiro Pino, Cecile M. Ronckers, Leontien C. Kremer, Paul W. Gidley, David R. Grosshans, Siddhartha Laskar, M. Fatih Okcu, Louis S. Constine, Arnold C. Paulino Tags: Clinical Investigation Source Type: research

The influence of patient-provider language concordance in cancer care: results of the Hispanic Outcomes by Language Approach (HOLA) randomized trial
Delivering linguistically competent care is critical to serving limited English proficiency (LEP) patients, and represents a key national strategy to help reduce health disparities. Current acceptable standards of communication with LEP patients include providers communicating through professional interpretive services, or bilingual providers speaking the patients ’ preferred language directly. This randomized clinical trial tests the impact of patient-provider language concordance on patient satisfaction. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Daniel M Seible, Souma Kundu, Alexa Azuara, Daniel R Cherry, Steven Arias, Vinit V Nalawade, Jonathan Cruz, Rolando Arreola, Maria Elena Martinez, Jesse N Nodora, Douglas A Rahn, James D Murphy Source Type: research

Evaluation of Long-term Outcomes and Toxicity after Stereotactic Phosphorus-32 Based Intracavitary Brachytherapy in Patients with Cystic Craniopharyngioma
Phosphorus-32-based interstitial brachytherapy has an established role as a minimally invasive treatment modality for patients with cystic craniopharyngioma. However, reporting on long-term outcomes with toxicity profiles for large cohorts is lacking in the literature. The purpose of this study is therefore to evaluate the long-term visual, endocrine and neurocognitive function in what is the largest patient series having received this treatment to date. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Xin Yu, Sebastian M Christ, Rui Liu, Yaming Wang, Chenhao Hu, Bo Feng, Anand Mahadevan, Ekkehard M Kasper Source Type: research

Preoperative radiosurgery for resected brain metastases: the PROPS-BM multicenter cohort study
Preoperative radiosurgery (SRS) is a feasible alternative to postoperative SRS with potential benefits in adverse radiation effect (ARE) and leptomeningeal disease (LMD) relapse. However, previous studies are limited by small patient numbers and single institutional design. Our aim was to evaluate preoperative SRS outcomes and prognostic factors from a large multicenter cohort (Trial name BLINDED). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Roshan S. Prabhu, Reshika Dhakal, Zachary K. Vaslow, Tu Dan, Mark V. Mishra, Erin S. Murphy, Toral R. Patel, Anthony L. Asher, Kailin Yang, Matthew A. Manning, Joseph D. Stern, Ankur R. Patel, Zabi Wardak, Graeme F. Woodworth, Samuel T. Chao, Alireza Moha Source Type: research

Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases
As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood –brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). The clinical value of cranial radiotherapy in osimertinib-treated NSCLC with BMs remains largely unknown. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Fan Yu, Jianjiao Ni, Wanqin Zeng, Yue Zhou, Tiantian Guo, Ya Zeng, Yang Zhao, Shuyan Li, Yida Li, Xi Yang, Liqing Zou, Shengping Wang, Quan Liu, Yuan Li, Li Chu, Xiao Chu, Luxi Ye, Wen Yu, Zhengfei Zhu Source Type: research

Joint optimization of photon – carbon ion treatments for Glioblastoma
We present a method to simultaneously optimize sequentially delivered intensity modulated photon (IMRT) and carbon ion (CIRT) treatments based on cumulative biological effect, incorporating both the variable RBE of carbon ions and the fractionation effect within the linear quadratic model. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Amit Ben Antony Bennan, Jan Unkelbach, Niklas Wahl, Patrick Salome, Mark Bangert Source Type: research

Patient-reported toxicity and quality of life profiles in head and neck cancer patients treated with definitive radiotherapy or chemoradiation
Radiotherapy is an effective but burdensome treatment for head and neck cancer (HNC). We aimed to characterize the severity and time pattern of patient-reported symptoms and quality of life in a large cohort of HNC patients treated with definitive radiotherapy, with or without systemic treatment. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 25, 2021 Category: Radiology Authors: Lisa Vanden Bosch, Hans Paul van der Laan, Arjen van der Schaaf, Sjoukje F. Oosting, Gyorgy B. Halmos, Max J.H. Witjes, Edwin Oldehinkel, Tineke W.H. Meijer, Johanna G.M. van den Hoek, Roel J.H.M. Steenbakkers, Johannes A. Langendijk Source Type: research

Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer
To review ten years of employing single-fraction lung SBRT (SF-SBRT) for medically inoperable peripheral early stage lung cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 25, 2021 Category: Radiology Authors: Gregory M.M. Videtic, Chandana A. Reddy, Neil M. Woody, Kevin L. Stephans Tags: Original Article Source Type: research

Proton Therapy for Breast Cancer: A Consensus Statement from the Particle Therapy Cooperative Group (PTCOG) Breast Cancer Subcommittee
Radiotherapy plays an important role in the multidisciplinary management of breast cancer. Recent years have seen improvements in breast cancer survival as well as a greater appreciation of potential long-term morbidity associated with the dose and volume of irradiated organs. Proton therapy reduces the dose to non-target structures while optimizing target coverage. However, there remain additional financial costs associated with proton therapy, despite reductions over time, and studies have yet to demonstrate that protons improve upon treatment outcomes achieved with photon radiotherapy. (Source: International Journal of ...
Source: International Journal of Radiation Oncology * Biology * Physics - May 25, 2021 Category: Radiology Authors: Robert W. Mutter, J. Isabelle Choi, Rachel B. Jimenez, Youlia M. Kirova, Marcio Fagundes, Bruce G. Haffty, Richard A. Amos, Julie A. Bradley, Peter Y. Chen, Xuanfeng Ding, Antoinette M. Carr, Leslie M. Taylor, Mark Pankuch, Raymond B. Mailhot Vega, Alice Tags: Critical Review Source Type: research

Developing a peptide that inhibits DNA repair by blocking the binding of Artemis and DNA Ligase IV to enhance tumor radiosensitivity
Artemis and DNA Ligase IV are two critical elements in the NHEJ pathway of DNA repair, acting as the nuclease and DNA ligase, respectively. Enhanced cellular radiosensitivity by inhibition of either protein contributes to a promising approach to develop molecular targeted radiosensitizers. The interaction between Artemis and DNA Ligase IV is required for the activation of Artemis as nuclease at 3 ’overhang DNA; thus, we aim to generate an inhibitory peptide targeting the interaction between Artemis and DNA Ligase IV for novel radiosensitizer development. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 24, 2021 Category: Radiology Authors: Chu Zhu, Xuanxuan Wang, Ping Li, Yanhong Zhu, Yikan Sun, Jiamiao Hu, Hai Liu, Xiaonan Sun Tags: Biology Contribution Source Type: research

ALKBH5-modified HMGB1-STING Activation Contributes to Radiation Induced Liver Disease Via Innate Immune Response
Radiation therapy (RT), vital for treatment of primary liver cancer, comes with unavoidable liver injury, which limits its implementation. N6-methyladenosine (m6A) methylation is involved in many molecular functions. However, its role in radiation-induced liver diseases (RILD) remains unknown. Here, we intend to investigate the role of m6A methylation in RILD. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 24, 2021 Category: Radiology Authors: Genwen Chen, Qianqian Zhao, Baoying Yuan, Biao Wang, Yang Zhang, Zongjuan Li, Shisuo Du, Zhaochong Zeng Tags: Biology Contribution Source Type: research

Can sex and seniority predict the quality of a journal reviewer's manuscript critique?
To evaluate reviewers ’ timeliness and review quality for the International Journal of Radiation Oncology, Biology, and Physics (IJROBP) by sex and seniority. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 23, 2021 Category: Radiology Authors: Daniel S. Jamorabo, Matthew P. Deek, Sue S. Yom, Hasan Rehman, Anthony L. Zietman, Sabin B. Motwani, William M. Briggs, Sinae Kim, Daniel T. Chang, Salma K. Jabbour Source Type: research

The role of adjuvant chemoradiotherapy in non-hilar extrahepatic bile duct cancer: A long term single institutional analysis
Despite frequent use in the clinical setting, especially for patients with high risk factors for relapse, the role of adjuvant treatment has not been clarified in non-hilar extrahepatic bile duct cancer (NH-EHBDC). The goal of this study is to identify the role of adjuvant chemoradiotherapy (CRT) in NH-EHBDC patients after radical surgery. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 20, 2021 Category: Radiology Authors: Won Ick Chang, Byoung Hyuck Kim, Hyun-Cheol Kang, Kyubo Kim, Kyung-Hun Lee, Do-Youn Oh, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Eui Kyu Chie Tags: Clinical Investigation Source Type: research

Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive anti-tumor immune defenses
We examined how radiation dose per fraction (DPF) and total dose, as represented by biological effective dose (BED), can independently and differentially affect the immunomodulatory capacity of radiation therapy (RT).Materials and Methods: AT3-OVA mammary and MC38 colorectal tumors in C57BL/6 mice were irradiated with rationally selected dose-fractionation schedules, alone or with immune-modulating or depleting agents. Tumor growth was monitored as a readout of therapeutic response. Flow cytometry and RNA sequencing of mouse tumors and analysis of transcriptomic datasets from irradiated human cancers were used to dissect t...
Source: International Journal of Radiation Oncology * Biology * Physics - May 20, 2021 Category: Radiology Authors: Joseph Sia, Jim Hagekyriakou, Ioana Chindris, Hassan Albarakati, Trevor Leong, Ramona Schlenker, Simon P. Keam, Scott G. Williams, Paul J. Neeson, Ricky W. Johnstone, Nicole M. Haynes Source Type: research

Reasons for Declining Applicant Numbers in Radiation Oncology from the Applicants ’ Perspective: Results from the XXX
Applications to radiation oncology in the United States have decreased the last three years resulting in unfilled residency positions (30 (14.5%) in 2019 and 35 (18.5%) in 2020). The aim of this study is to understand the concerns among radiation oncology applicants and whether these concerns may have led to a decline in applications. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 19, 2021 Category: Radiology Authors: Jared Alexander Maas, Omer Lee Burnett, Samuel Ray Marcrom Tags: Clinical Investigation Source Type: research

In Reply to Schultheiss
We thank Dr Schultheiss for his interest in our publication,1 his valuable insights, and for highlighting the excellent didactic paper by Dr David F. Herring2 that provided the pioneering foundations for use of statistical approaches, including maximum likelihood and testing the fit in dose response modeling. Our paper aimed to demonstrate in a practical step-by-step manner the full process of building a dose response model starting with data-driven approaches and describing potential pitfalls for practitioners and newbies to the field. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 18, 2021 Category: Radiology Authors: Vitali Moiseenko, Jona A. Hattangadi-Gluth, Minh-Phuong Huynh-Le, Lawrence B. Marks, Jimm Grimm, Michael T. Milano, Andrew Jackson, Ellen Yorke, Niclas Pettersson, Issam El Naqa Tags: Comments Source Type: research

Validating Modern NRG Oncology Pelvic Nodal and GFRU Prostate Bed Contouring Guidelines for Post-prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial
We used the patterns of recurrence on 18F-fluciclovine PET/CT in post-prostatectomy patients enrolled in the XXXX trial to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radioth érapie Urologique (GFRU) contouring recommendations encompassed all sites of recurrence in the prostate fossa and pelvic nodes in comparison to former Radiation Therapy Oncology Group (RTOG) recommendations. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 17, 2021 Category: Radiology Authors: Grant Harmon, Dennis Chan, Brian Lee, Chelsea Miller, Alex Gorbonos, Gopal Gupta, Marcus Quek, Michael Woods, Bital Savir-Baruch, Matthew M. Harkenrider, Abhishek A. Solanki Tags: Clinical Investigation Source Type: research